Browsing Tag
AFT Pharmaceuticals
4 posts
Stablepharma begins pivotal trial of fridge-free vaccine stable for 24 months at 30°C
Stablepharma has started a 160-participant Phase 2b trial of its thermostable tetanus-diphtheria vaccine, advancing a technology that could reduce dependence on refrigeration while opening commercial opportunities in vaccine distribution and temperature-sensitive medicines.
Stablepharma company profile: Business model, pipeline, and growth outlook (2026 edition)
Stablepharma is a UK biotech developing fridge-free vaccines and injectables via its StablevaX platform. Explore its Phase 1 pipeline, AFT Pharmaceuticals partnership, and 2026-2027 growth outlook.
No fridge, no problem: Stablepharma and AFT join forces to make critical drugs shelf-stable
Stablepharma and AFT team up to develop fridge-free cancer and infection drugs. Find out how this could reshape pharma logistics and global access.
Is AFT Pharmaceuticals undervalued after NZ$208m in FY25 Revenue? What’s next for AFP stock
AFT Pharmaceuticals posts NZ$208M record revenue in FY25. Find out why investors are eyeing its NZ$300M growth target despite short-term profit dips.